Genentech to manufacture tocilizumab under contract
This article was originally published in Scrip
Genentechhas entered an agreement to manufacture bulk supplies of the anti-interleukin-6 receptor antibody Actemra (tocilizumab) forChugai, its sister company under the Roche umbrella. Chugai will continue to manufacture bulk quantities and formulate the product at a facility in Japan, which was originally expected to be able to meet global demand. Rather than invest in additional domestic capacity, a decision has taken to outsource production to Genentech's Vacaville site in California, Chugai said. Actemra is already marketed in Japan for arthritis and Castleman's disease and has just been recommended for approval in the US for rheumatoid arthritis.
You may also be interested in...
Shionogi’s once-daily oral COVID-19 antiviral finally gets Japan approval after being considered for the third time by an expert panel, paving the way for public availability of the country’s first such home-grown option in early December.
Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.
In this week's podcast version of Five Must-Know Things: Pfizer’s COVID transition; Lilly ramps up Mounjaro on strong demand; Pfizer’s R&D head reflects on pandemic experience; parsing Novartis’s Q3; and China’s progress with mRNA vaccines.